Fesilty is supplied as a lyophilized powder for reconstitution in a single-dose vial containing approximately 1g of human fibrinogen.

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

USF Health preclinical discovery may help identify new therapeutic targets for Alzheimer’s disease, traumatic brain injury and other neurodegenerative diseases The findings have implications for ...

The fibrinogen concentrate is approved for children and adults with acute bleeding related to certain types of congenital ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT ® ...

The top panel, designed with BioRender.com, illustrates the process of clot formation and lysis, beginning with platelet aggregation and activation of the coagulation cascade, followed by the ...

Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency 10.06.2022 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS ...

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

Before soluble fibrinogen, a blood plasma protein, is converted into insoluble fibrin molecules that can toxically accumulate outside blood vessels in the brain, fibrinogen connects directly with ...